|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
674,040,000 |
Market
Cap: |
16.71(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.15 - $26.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Avantor is a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education and government and advanced technologies and applied materials industries. Co.'s portfolio includes: Materials and consumables, such as lab products and supplies, formulated silicone materials, customized excipients, and customized single-use assemblies; equipment and instrumentation, such as filtration systems, virus inactivation systems, and incubators; and services and specialty procurement, such as onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
27,500 |
Total Buy Value |
$0 |
$0 |
$0 |
$573,100 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
27,872 |
27,872 |
60,449 |
163,424 |
Total Sell Value |
$687,456 |
$687,456 |
$1,380,595 |
$4,309,849 |
Total People Sold |
3 |
3 |
4 |
5 |
Total Sell Transactions |
4 |
4 |
6 |
15 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Vanderhaegen Frederic |
EVP, Americas & Europe |
|
2022-02-25 |
4 |
D |
$35.39 |
$7,644 |
D/D |
(216) |
167,974 |
|
- |
|
Lewis Sheri |
EVP, Global Ops & Supply Chain |
|
2022-02-25 |
4 |
D |
$35.39 |
$40,238 |
D/D |
(1,137) |
71,448 |
|
- |
|
Couturier Christophe |
EVP, AMEA |
|
2022-02-25 |
4 |
D |
$35.39 |
$16,527 |
D/D |
(467) |
115,128 |
|
- |
|
Stubblefield Michael |
CEO |
|
2022-02-25 |
4 |
D |
$35.39 |
$278,378 |
D/D |
(7,866) |
1,313,041 |
|
- |
|
Henson Meghan |
EVP, Chief HR Officer |
|
2022-02-25 |
4 |
D |
$35.39 |
$32,948 |
D/D |
(931) |
31,405 |
|
- |
|
Szlosek Thomas A |
EVP & CFO |
|
2022-02-25 |
4 |
D |
$35.39 |
$72,302 |
D/D |
(2,043) |
252,746 |
|
- |
|
Miller Justin |
EVP & General Counsel |
|
2022-02-25 |
4 |
D |
$35.39 |
$20,632 |
D/D |
(583) |
92,247 |
|
- |
|
Eck Steven W |
SVP & Chief Accounting Officer |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,138 |
18,838 |
|
- |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
15,110 |
140,291 |
|
- |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2022-02-23 |
4 |
AS |
$33.79 |
$103,364 |
D/D |
(3,059) |
125,181 |
|
-5% |
|
Vanderhaegen Frederic |
EVP, Americas & Europe |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
15,110 |
168,190 |
|
- |
|
Lewis Sheri |
EVP, Global Ops & Supply Chain |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
9,822 |
72,585 |
|
- |
|
Couturier Christophe |
EVP, AMEA |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,044 |
115,595 |
|
- |
|
Stubblefield Michael |
CEO |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
69,885 |
1,320,907 |
|
- |
|
Henson Meghan |
EVP, Chief HR Officer |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
8,311 |
32,336 |
|
- |
|
Szlosek Thomas A |
EVP & CFO |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
16,621 |
254,789 |
|
- |
|
Miller Justin |
EVP & General Counsel |
|
2022-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
92,830 |
|
- |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2022-02-20 |
4 |
D |
$34.00 |
$104,448 |
D/D |
(3,072) |
128,240 |
|
- |
|
Stubblefield Michael |
President and CEO |
|
2022-02-20 |
4 |
D |
$34.00 |
$372,606 |
D/D |
(10,959) |
1,251,022 |
|
- |
|
Miller Justin |
EVP & General Counsel |
|
2022-02-20 |
4 |
D |
$34.00 |
$45,152 |
D/D |
(1,328) |
86,030 |
|
- |
|
Eck Steven W |
SVP & Chief Accounting Officer |
|
2022-02-20 |
4 |
D |
$34.00 |
$15,232 |
D/D |
(448) |
13,700 |
|
- |
|
Szlosek Thomas A |
EVP & CFO |
|
2022-02-20 |
4 |
D |
$34.00 |
$137,360 |
D/D |
(4,040) |
238,168 |
|
- |
|
Couturier Christophe |
EVP, AMEA |
|
2022-02-20 |
4 |
D |
$34.00 |
$43,078 |
D/D |
(1,267) |
109,551 |
|
- |
|
Vanderhaegen Frederic |
EVP, Europe |
|
2022-02-20 |
4 |
D |
$28.69 |
$11,419 |
D/D |
(398) |
153,080 |
|
- |
|
Murray Mark Christopher |
EVP, Biomaterials & AT |
|
2022-01-13 |
4 |
D |
$37.50 |
$34,425 |
D/D |
(918) |
18,680 |
|
- |
|
534 Records found
|
|
Page 8 of 22 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|